These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 30962732)

  • 21. RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
    Hayashi T; Odintsov I; Smith RS; Ishizawa K; Liu AJW; Delasos L; Kurzatkowski C; Tai H; Gladstone E; Vojnic M; Kohsaka S; Suzawa K; Liu Z; Kunte S; Mattar MS; Khodos I; Davare MA; Drilon A; Cheng E; Stanchina E; Ladanyi M; Somwar R
    Dis Model Mech; 2020 Dec; 14(2):. PubMed ID: 33318047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
    Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
    J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
    Drilon A; Fu S; Patel MR; Fakih M; Wang D; Olszanski AJ; Morgensztern D; Liu SV; Cho BC; Bazhenova L; Rodriguez CP; Doebele RC; Wozniak A; Reckamp KL; Seery T; Nikolinakos P; Hu Z; Oliver JW; Trone D; McArthur K; Patel R; Multani PS; Ahn MJ
    Cancer Discov; 2019 Mar; 9(3):384-395. PubMed ID: 30487236
    [No Abstract]   [Full Text] [Related]  

  • 24. Targeting RET-rearranged lung cancers with multikinase inhibitors.
    Sabari JK; Siau ED; Drilon A
    Oncoscience; 2017 Mar; 4(3-4):23-24. PubMed ID: 28540330
    [No Abstract]   [Full Text] [Related]  

  • 25. Decade in review: a new era for RET-rearranged lung cancers.
    Choudhury NJ; Drilon A
    Transl Lung Cancer Res; 2020 Dec; 9(6):2571-2580. PubMed ID: 33489819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
    Drilon A; Lin JJ; Filleron T; Ni A; Milia J; Bergagnini I; Hatzoglou V; Velcheti V; Offin M; Li B; Carbone DP; Besse B; Mok T; Awad MM; Wolf J; Owen D; Camidge DR; Riely GJ; Peled N; Kris MG; Mazieres J; Gainor JF; Gautschi O
    J Thorac Oncol; 2018 Oct; 13(10):1595-1601. PubMed ID: 30017832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Dacomitinib and Selpercatinib Treatment for a Patient with
    Liu CY; Liu CH
    Onco Targets Ther; 2024; 17():499-506. PubMed ID: 38911906
    [No Abstract]   [Full Text] [Related]  

  • 28. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
    Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pralsetinib for the treatment of a
    Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
    Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
    Lin JJ; Kennedy E; Sequist LV; Brastianos PK; Goodwin KE; Stevens S; Wanat AC; Stober LL; Digumarthy SR; Engelman JA; Shaw AT; Gainor JF
    J Thorac Oncol; 2016 Nov; 11(11):2027-2032. PubMed ID: 27544060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and optimization of selective RET inhibitors via scaffold hopping.
    Luo Z; Wang L; Fu Z; Shuai B; Luo M; Hu G; Chen J; Sun J; Wang J; Li J; Chen S; Zhang Y
    Bioorg Med Chem Lett; 2021 Sep; 47():128149. PubMed ID: 34058344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.
    Sarfaty M; Moore A; Neiman V; Dudnik E; Ilouze M; Gottfried M; Katznelson R; Nechushtan H; Sorotsky HG; Paz K; Katz A; Saute M; Wolner M; Moskovitz M; Miller V; Elvin J; Lipson D; Ali S; Gutman LS; Dvir A; Gordon N; Peled N
    Clin Lung Cancer; 2017 Jul; 18(4):e223-e232. PubMed ID: 28082048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case report: identification of
    Ma J; Wang B; Meng E; Meng X
    Gland Surg; 2021 Sep; 10(9):2874-2879. PubMed ID: 34733735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catalog of 5' fusion partners in
    Ou SI; Zhu VW
    JTO Clin Res Rep; 2020 Jun; 1(2):100037. PubMed ID: 34589933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
    Acharya B; Frett B
    Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-small-cell lung cancer: how to manage
    Andrini E; Mosca M; Galvani L; Sperandi F; Ricciuti B; Metro G; Lamberti G
    Drugs Context; 2022; 11():. PubMed ID: 35912003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells.
    Codony-Servat J; García-Roman S; Molina-Vila MÁ; Bertran-Alamillo J; Viteri S; d'Hondt E; Rosell R
    Transl Oncol; 2021 Jan; 14(1):100887. PubMed ID: 33129112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
    Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
    Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
    Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T
    Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.